Merck & Company (MRK) Stock Price, Quote & News

Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health manageme...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 908 740 4000

Website: www.merck.com

Address:

126 East Lincoln Avenue, Rahway, United States

ShadowBanningIsBad Mar. 17 at 3:27 AM

$XBI $PFE $MRNA $GSK $MRK we were always taught decisions were made by represnatives. Some people know by preschool that judges and un elected twats run things. Where I reside no one takes vaccines. Few people have any disease or ever see a doctor from 10 to 60. Americans should be vaccinated.

0 · Reply

AL912 Mar. 17 at 2:53 AM

$IBRX $SPY $XBI WHY ANKTIVA RESCUES MERCK’S BCG CRISIS 🤝 A massive misunderstanding by retail: Anktiva doesn't replace BCG; it saves it. $MRK is the sole global manufacturer of TICE BCG. They are in a multi-year shortage, operating at maximum capacity. Clinics are forced to ration doses, cutting maintenance therapies short. Anktiva (IL-15) supercharges the limited BCG supply. The QUILT-3.032 data proves it extends the duration of response past 45 months. It prevents patients from needing constant, BCG-heavy retreatments. With the NCCN now explicitly recommending Anktiva for the massive Papillary cohort, urologists can finally protect their BCG supply while delivering an 82% cystectomy avoidance rate. It is a mandatory supply-chain fix disguised as a therapeutic.

1 · Reply

RonIsWrong Mar. 17 at 12:51 AM

$XBI Judge Strikes Down Kennedy’s Vaccine Policies cc $PFE $MRNA $GSK $MRK Ruling on a lawsuit brought by several prominent medical organizations, a district court said the federal government had not based its decisions on science in limiting Covid shots and revising the childhood immunization schedule.

2 · Reply

XRPHomie Mar. 17 at 12:04 AM

$IBRX $MRK $IBRX PSS will Never sell $IBRX IMHO

0 · Reply

mcstoxdox Mar. 17 at 12:00 AM

$BTC.X $IBRX $MRK $SPY lack of cytokine storms is hige, was talking anktiva to some doc friends and they were all” but immunotherapy, dangerous, hospitalization etc“. .True. But we aint got that. We got

0 · Reply

AL912 Mar. 16 at 11:57 PM

$IBRX $SPY $BTC.X 🧬 STOP THINKING OF $IBRX AS JUST A BLADDER CANCER PLAY 🧬 If you understand the science of Anktiva, you realize why this is a multi-billion dollar buyout target. Old immunotherapies used IL-2, which was highly toxic. Anktiva is an IL-15 Superagonist. It binds to the IL-15 receptor, proliferating Natural Killer (NK) and CD8+ Killer T-cells by up to 10,000x without the toxicity. But the Holy Grail? It generates Memory T-Cells. It trains the immune system to remember the cancer, providing durable responses stretching past 45 months. 🌍 The Global Proof: They just got approval for Non-Small Cell Lung Cancer (NSCLC) in Saudi Arabia. It’s the FIRST IL-15 approved for solid tumors anywhere. 🎯 The Endgame: They are running QUILT trials combining Anktiva with Keytruda ($MRK). If Anktiva proves it can rescue solid tumor patients who have stopped responding to Keytruda, $IBRX becomes the universal combo-therapy for the highest-grossing drug on earth.

1 · Reply

TechTraderGrok Mar. 16 at 10:27 PM

Sold $MRK at $115.4 (-0.7%). From Grok: "MRK has weakened since our entry at $116.21, with four consecutive lower closes and steady selling pressure that broke recent support levels around $115. " https://www.techtrader.ai/grokwall/?post=16983&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

taxplanr Mar. 16 at 9:40 PM

Will the road block that has kept the Trump admin from pulling the mRNA bioweapon off the market gotten the message? $BNTX $MRNA $PFE $MRK $BMY

0 · Reply

Doxtator Mar. 16 at 2:31 PM

$BMEA Biomea Fusion has a Phase 1 obesity trial running for its oral GLP-1 candidate BMF-650. We have a near term readout of 28-day weight loss data expected in Q2 2026. But what makes Biomea even more interesting is their other asset. Icovamenib (their menin inhibitor) has shown in preclinical work that when paired with GLP-1 therapy it may enhance metabolic efficiency while preserving lean muscle mass vs GLP-1 alone. If that concept translates clinically, it opens the door to a metabolic stack: GLP-1 for appetite suppression + menin inhibition for improved metabolic function. So the near-term catalyst is the BMF-650 Phase 1 readout, but the longer-term thesis could be the combination approach. Worth keeping on the radar, this company is still very small, and BMF-650 is only in Phase 1, and Icovamenib Phase 2 but if I’m watching these results I can only assume Lilly, Merck and Novo are too. $LLY $MRK $NVO

1 · Reply

taxplanr Mar. 16 at 2:23 PM

Ivermectin Fenbendazole and Mebendazole curing Pancreatic Cancer $BNTX $MRNA $BMY $MRK https://makisw.substack.com/p/ivermectin-fenbendazole-and-mebendazole-a39?utm_source=post-email-title&publication_id=1385328&post_id=191125750&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email

0 · Reply

Merck Highlights New Data from Cardio-Pulmonary Pipeline at ACC.26 Showcasing Commitment to Advance Innovative Research

Mar 11, 2026, 8:18 AM EDT - 5 days ago

Harbor Health Care ETF Q4 2025 Portfolio Review

ABBV ABVX GMAB LLY MASI MEDI RVMD

Mar 4, 2026, 8:00 AM EST - 12 days ago

NeOnc Technologies Reports Phase 1 Dose-Escalation Results for Dosing and Toxicity and Determination of Recommended Phase 2 Dose for Oral NEO212; Management to Host KOL Conference Call Today at 9 a.m. ET

NTHI

Mar 3, 2026, 3:42 PM EST - 13 days ago

Merck & Co., Inc. (MRK) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 3, 2026, 2:33 PM EST - 13 days ago

AI-Powered Tempus Inks New Multi-Year Merck Deal

TEM

Feb 28, 2026, 10:05 AM EST - 16 days ago

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

Feb 28, 2026, 10:00 AM EST - 16 days ago

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

Feb 27, 2026, 12:33 PM EST - 17 days ago

Merck to lay off around 150 employees at US site amid slump in Gardasil sales

Feb 27, 2026, 10:15 AM EST - 17 days ago

KEYTRUDA® (pembrolizumab) Plus Paclitaxel With or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival (OS) Versus Paclitaxel With or Without Bevacizumab in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Feb 27, 2026, 10:00 AM EST - 17 days ago

KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Feb 26, 2026, 8:00 AM EST - 18 days ago

Synthekine Announces Clinical Trial Collaboration with Merck to Evaluate STK-012 In Combination with Keytruda® (Pembrolizumab) and Chemotherapy in Ongoing Randomized Phase 2 Trial in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer

Feb 26, 2026, 7:30 AM EST - 18 days ago

Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie

ABBV

Feb 25, 2026, 4:30 PM EST - 19 days ago

FDA Approves NUMELVI™ (atinvicitinib tablets) for Dogs from Merck Animal Health – The First and Only Second-Generation Janus Kinase (JAK) Inhibitor for the Control of Pruritus Associated with Allergic Dermatitis

Feb 25, 2026, 12:38 PM EST - 19 days ago

Merck's New HIV Drug Shows Promise. Its Chief Medical Officer Explains Why Wall Street Should Care.

Feb 25, 2026, 12:37 PM EST - 19 days ago

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Feb 24, 2026, 6:45 AM EST - 20 days ago

Merck to Participate in the TD Cowen 46th Annual Health Care Conference

Feb 23, 2026, 3:15 PM EST - 21 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRNA PFE

Feb 23, 2026, 9:11 AM EST - 21 days ago

Merck creates separate oncology arm ahead of Keytruda patent loss

Feb 23, 2026, 7:38 AM EST - 21 days ago

Merck Creates Separate Cancer Business. The Stock Is Rising Ahead of Patent Cliff.

Feb 23, 2026, 6:45 AM EST - 21 days ago

Merck Evolves Human Health Operating Structure to Support Portfolio Execution

Feb 23, 2026, 6:22 AM EST - 21 days ago

Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports

Feb 23, 2026, 6:00 AM EST - 21 days ago

Merck is establishing a separate cancer unit. The reorganization of its pharmaceutical business is aimed at bolstering product launches ahead of a key patent loss.

Feb 23, 2026, 5:12 AM EST - 21 days ago

Harbor Large Cap Value Fund Q4 2025 Portfolio Review

AMGN CBSH COF DHR LEN MSFT PH

Feb 22, 2026, 8:00 AM EST - 22 days ago

Merck: Why Investors Should Remain Bullish Despite Patent Risks

Feb 19, 2026, 5:15 AM EST - 25 days ago

Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons

Feb 18, 2026, 1:05 PM EST - 26 days ago

Merck Inks AI Drug Discovery Deal With Mayo Clinic To Revolutionize Drug Discovery

Feb 18, 2026, 6:45 AM EST - 26 days ago

Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine

Feb 16, 2026, 10:58 AM EST - 4 weeks ago

Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors

AMD GOOG LLY ORCL ZTS

Feb 12, 2026, 9:00 AM EST - 4 weeks ago

Merck: Keytruda Remains Resilient Despite LOE Risks - Buy Upon Correction

Feb 12, 2026, 8:05 AM EST - 4 weeks ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Feb 12, 2026, 6:45 AM EST - 4 weeks ago

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Feb 11, 2026, 6:45 AM EST - 4 weeks ago

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment

Feb 10, 2026, 4:35 AM EST - 4 weeks ago

Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform

Feb 9, 2026, 1:32 PM EST - 5 weeks ago

Merck: The Spike Doesn't Make It Overvalued

Feb 9, 2026, 9:55 AM EST - 5 weeks ago

Merck: A Buy For 2026, But The Clock Is Still Ticking

Feb 8, 2026, 10:28 PM EST - 5 weeks ago

From Bargain To Balancing Act: Merck's Next Test Begins (Rating Downgrade)

Feb 8, 2026, 9:56 PM EST - 5 weeks ago

Merck: Pipeline Building Despite The Light FY26 Guide, Major Momentum

Feb 4, 2026, 8:15 AM EST - 5 weeks ago

CANCER BREAKTHROUGH: Moderna, Merck report cancer discovery

MRNA

Feb 3, 2026, 1:30 PM EST - 5 weeks ago

Merck & Co., Inc. (MRK) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 11:17 AM EST - 5 weeks ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

PFE

Feb 3, 2026, 11:06 AM EST - 5 weeks ago

Merck's Annual Outlook Falls Short But Keytruda, Animal Health Segments Grow

Feb 3, 2026, 7:14 AM EST - 5 weeks ago

Merck tops Q4 earnings expectations but issues weaker 2026 outlook

Feb 3, 2026, 6:55 AM EST - 5 weeks ago

Merck's outlook for 2026 comes in lower-than-expected as pipeline faces make-or-break year

Feb 3, 2026, 6:48 AM EST - 5 weeks ago

Merck Earnings Top Estimates. Why the Stock Is Falling.

Feb 3, 2026, 6:38 AM EST - 5 weeks ago

Merck Expects Slower Earnings Growth As It Spends on Acquisitions

Feb 3, 2026, 6:34 AM EST - 5 weeks ago

Merck forecasts 2026 sales below estimates on patent losses

Feb 3, 2026, 6:31 AM EST - 5 weeks ago

Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms

Feb 3, 2026, 6:30 AM EST - 5 weeks ago

Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

Jan 30, 2026, 1:09 PM EST - 6 weeks ago

5 Stocks That Could Outperform Even in a Pullback

HON MSFT PG

Jan 28, 2026, 11:10 AM EST - 6 weeks ago

What's Fueling The Rally In Merck Stock?

ShadowBanningIsBad Mar. 17 at 3:27 AM

0 · Reply

AL912 Mar. 17 at 2:53 AM

1 · Reply

RonIsWrong Mar. 17 at 12:51 AM

2 · Reply

XRPHomie Mar. 17 at 12:04 AM

$IBRX $MRK $IBRX PSS will Never sell $IBRX IMHO

0 · Reply

mcstoxdox Mar. 17 at 12:00 AM

0 · Reply

AL912 Mar. 16 at 11:57 PM

1 · Reply

TechTraderGrok Mar. 16 at 10:27 PM

0 · Reply

taxplanr Mar. 16 at 9:40 PM

Will the road block that has kept the Trump admin from pulling the mRNA bioweapon off the market gotten the message? $BNTX $MRNA $PFE $MRK $BMY

0 · Reply

Doxtator Mar. 16 at 2:31 PM

1 · Reply

taxplanr Mar. 16 at 2:23 PM

0 · Reply

TeresaTrades Mar. 16 at 1:37 PM

Largest CALL OI decreases $AAPL $NVDA $LUV $WBD $MRK

0 · Reply

SenefAS Mar. 16 at 10:50 AM

Canaccord just upgraded Seres Therapeutics with a $22 price target. With the stock currently at $8.63, that’s a potential upside of roughly +155% (Ser 155 🙃) But the upgrade isn’t the only thing catching attention. With Seres’ assets, its strategic positioning, and growing interest from larger players in the microbiome space, a buyout scenario is becoming increasingly realistic. The valuation gap is huge, and Seres could be a fast, strategic acquisition for any pharma looking to strengthen its pipeline. This upgrade might be the first real signal. $MCRB $MRK $NSRGY #Canaccord #BuyoutPotential

0 · Reply

taxplanr Mar. 15 at 1:57 PM

Peer reviewed study finds mRNA alters genes causing uniniended gene expressions $BNTX $MRNA $MRK $BMY Uncontrollable platform https://aapsonline.org/covid-mrna-vaccines-may-alter-gene-expression-according-to-journal-of-american-physicians-and-surgeons/

0 · Reply

taxplanr Mar. 15 at 3:04 AM

Warnings going out about $MRK rabies pet vaccines being self amplifying and infecting pet owners https://www.instagram.com/reel/DVyZRxFDrFv/?igsh=MTBxYWx1cHQzZWM1dQ==

0 · Reply

QuantInsider Mar. 14 at 1:16 AM

$MRK saw a big move on the options tape today Around 3:22pm, about 40,000 deep ITM calls traded in seven large blocks for 3/20 expiry That's a ~$102.6M premium, way above existing open interest at the $70 to $90 strikes Price stayed flat, down 0.25% today with no news driving this Feels like complex institutional positioning rather than a clear upside signal Implied vols are high, around 130 to 280% plus, so I'm not jumping in on these calls yet Watching how Monday's open interest shifts and price action around those strikes This one's on the watchlist for now

0 · Reply

clan Mar. 13 at 11:31 PM

$MNKD We know Cipla $CIPLA.NSE has a DPI facility in NY (for Indian Afrezza[?]). Will B.I. build their own DPI facility, or will Mannkind make all the TechnOFEV in Danbury? $MRK $JNJ

0 · Reply

biolover Mar. 13 at 3:29 PM

$GPCR $VKTX structure has data this month. It is tiny 18 pt arm. But it is a bipolar market and clearly doesn’t understand data at first glance. I had big position in structure and I sold after Lilly attain 1. I don’t beleive in the whole small mole anymore. But all obesity biotech been undervalued vs crazy valuations for others. So people could still do well on structure if data show further wt loss. I would not hold it through the summer as high chance $LLY drug will start showing liver toxicity. It looks peptides may still dominate as injections and orally. Even the incompetent $MRK management could ask their MDs and look at liver enzymes issues.

0 · Reply

taxplanr Mar. 13 at 2:00 PM

There won't be a cancer market left for $BNTX $MRNA $BMY $MRK https://stocktwits.com/news-articles/markets/equity/why-ibrx-rising-today-nk-cell-therapy-update/cZdDfe3RIas

1 · Reply

breakoutstock Mar. 13 at 7:43 AM

$NKTR folks to give you an idea of the size of the market for REZPEG in 2030 the only Drug that does $30B in sales now is Keytruda. Which accounts for 1/2 of $MRK market cap of $287B Thus in theory if all goes well we could see $130B market cap if it takes over Dupi too.

0 · Reply

Chemaster Mar. 13 at 4:01 AM

$MAIA The 2028 patent cliff poses a $170-350B revenue risk for Big Pharma through 2032, with oncology heavyweights like Merck's Keytruda ($30B annual sales) losing U.S. exclusivity, enabling biosimilars and generics to erode markets—driving urgent M&A (e.g., $173B in at-risk sales by 2032) for innovative assets like MAIA Biotechnology ($MAIA) THIO to fill gaps in immuno-oncology pipelines. THIO's differentiated mechanism, high Phase 3 success probability (96-99% Bayesian), and pan-cancer appeal make it a prime partnership/acquisition target for firms like Merck ($MRK), Bristol Myers Squibb ($BMY), or Pfizer ($PFE) seeking post-cliff growth in a $668B oncology market by 2034. More Information at MAIA Unofficial Reddit Community https://www.reddit.com/r/MAIABiotech/comments/1rscru9/2028_patent_cliff_for_big_pharma/

0 · Reply

truehealthvalue Mar. 12 at 8:40 PM

$MRK take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position

0 · Reply

crtlabz Mar. 12 at 7:38 PM

$MRK

0 · Reply

Market Cap	285.83B
Revenue (ttm)	65.01B
Net Income (ttm)	18.25B
EPS (ttm)	N/A
PE Ratio	12.89
Forward PE	22.45
Profit Margin	28.08%
Debt to Equity Ratio	0.89

Volume	8,785,300
Avg Vol	12,299,968
Day's Range	N/A - N/A
Shares Out	2.47B
Stochastic %K	23%
Beta	0.27
Analysts	Strong Sell
Price Target	$129.30